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Encorton) with typing HPV 6,16 which were previously 
detected in anogenital region of the patients. 
One hundred recipients (20-65 aged) 0.5-18 years 
after allotransplantation were assessed clinically and 
histologically including biopsy of oral mucous and PCR 
techniques for HPV identification. Primers specific for 
E4 (HPV 6) and E6 (HPV 16) ORF were used for the 
amplification of HPV DNA present in samples. 
Epithelial verrucas differentiated in size, morphology 
and placement were found clinically in 10% patients. 
Thick, acantotic changed epithelium with numerous 
coilocytes and clear hiperproliferation was revealed in 
samples taken 
from all patients with the viral infection.Type 16 HPV 
were detected in 24% (24/100) of the recipients, type 6 
HPV occurred in 5% (5000) while both 16 HPV and 6 
HPV were revealed in 3 patients only. 
Our data indicate that the recipients with decreased 
immune response, the HPV infection and the chronic 
immunosuppression are at a major risk for the develop- 
ment of the oral neoplasm proliferations. The long term 
follow-up for detection of the oncogenic virus type as 
well as monitoring of the level of the immunosup- 
pression should be undertaken for protection against the 
development of the oral cancer in the kidney recipients. 
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The aim of this study was to assess the data related to 
human cytomegalovirus (HCMV) of renal transplant 
recipients in our transplantation center. Between April 
2000 and March 2002,109 consecutive renal transplants 
(53 cadaveric, 56 living-related) were performed in our 
center. All the donors and recipients were HCMV 
seropositive (D +/R+). Living-related recipients received 
prednisolonelmycophenolate mofetil cyclosporine or 
tacrolimus as an immunosuppressive regimen. Cadaveric 
recipients received the same triple therapy plus poly- 
clonal antibody for 7 to 14 days as induction. Polyclonal 
antibody therapy was also given in acute vascular or 
clinically severe rejection episodes. In all patients, 
acyclovir or valaciclovir was given as a prophylactic 
treatment for six months. Evidence of HCMV infection 
was monitored by HCMV antigenemia assay weekly 
for three months, biweekly for 3-6 months and then 
monthly up to one year after transplantation. HCMV 
antigenemia was positive (median: 6.5/2X lo5 PBL, 
range: 1-924/2x lo5 PBL) in 50 of 109 (45%) recipients 
(cadaveric: 41%, living-related: 16%). The median time 
for first positive antigenemia was 54 (3-145) days. 
Seventeen of the 31 antigenemia positive recipients had 
high level antigenemia (250/2x 10” PBL) and six of 
them developed HCMV disease (p<O.OOl). Twenty-six 
of 31 patients received ganciclovir for 20.4k2.7 days. 
HCMV infection and disease rates were higher in 
cadaveric recipients (p<O.OOl, p=O.O8, respectively). 
The risks of leucopenia and increment in transaminase 
levels were higher if first antigenemia level was high 
(p=O.O34, p=O.O14, respectively). HCMV infection and 
disease have been seen more frequently in thymo- 
globulin receiving patients than in ATG group (Thymo- 
globulin:5/6, ATG:l/B). Acute rejection rate was higher 
in HCMV antigenemia positive recipients than in 
negative recipients (28% vs. 13%; p=O.O61). Four of six 
recipients (12%) who have the disease died due to 
HCMV in the follow-up period. Our results suggested 
that polyclonal antibody treatment increases the rate of 
HCMV infection. We believe that monitoring of HCMV 
infection by antigenemia assay is a reasonable procedure 
and if antigen level is higher than r50/2x105 PBL, 
ganciclovir must be initiated, especially in recipients 
with leucopenia and high transaminase levels. 
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During the first two decades after 1958 when Anstrom 
et al first identified promyelocytic leukemia (PML), there 
were fewer than 100 pathologically confirmed cases of 
the disease. The diagnosis was most likely to be found in 
association with hematologic malignancies. With the 
onset of the HIV/AIDS epidemic the number of cases 
of PML escalated and the diagnosis became a relative 
frequent and important consideration in patients with 
advanced immunosuppression. In the summer of 2001 a 
33-year-old female patient with a subacute presentation 
of motor deficits was transferred to our hospital. 
The patient had a 6-month history of progressive 
motor deficits with periodic attenuation but without 
return to base line function. At admission she was bed 
bound without movement of her left extremities and of 
her right lower extremity. A month before admission she 
had been in rehabilitation ambulating and performing 
her own activities of daily living. She had a cushingoid 
appearance. Over the prior 6 months serial CT and MRI 
brain scans had shown lesions reported to represent 
cerebrovascular accidents. She had a history of SLE 
diagnosed when she was 6 years old. In 1979 the diag- 
nosis was confirmed by renal and skin biopsies. Through- 
out childhood and adolescence she had received 
symptomatic relief with prednisone therapy. In the late 
winter of 2000 she had exacerbations of symptoms 
attributed to SLE and been treated with prednisone in 
